Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Dehydration and Electrolyte Imbalance GLP-1 medications can cause nausea, vomiting, and diarrhea, particularly during dose escalation
Boost Endurance & Athletic Performance
Meta-analyses of these and other studies have demonstrated: Reductions in total cholesterol typically in the range of 15% from baseline, varying by agent and population Decreases in LDL cholesterol ranging from 17%, generally more modest than dedicated lipid-lowering therapies Reductions in triglycerides of 515%, with greater effects often seen in those with higher baseline levels Variable effects on HDL cholesterol , with small increases (1-2%) or neutral effects reported The magnitude of lipid improvements appears to correlate with the degree of weight loss achieved, suggesting that metabolic benefits may be partially mediated through adiposity reduction
Retatrutide, also known as LY3437943, is a peptide-class triple agonist that activates the GIP, GLP-1, and glucagon receptors, but it is not currently FDA-approved for any indication and is not available as an approved prescription product 1, 2, 3
